Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

294 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Drug interactions of lipid-altering drugs.
Bays HE, Dujovne CA. Bays HE, et al. Drug Saf. 1998 Nov;19(5):355-71. doi: 10.2165/00002018-199819050-00003. Drug Saf. 1998. PMID: 9825949 Review.
Lipid-altering drugs in development.
Bays HE, Dujovne CA. Bays HE, et al. Drugs R D. 1999 Jun;1(6):463-9. doi: 10.2165/00126839-199901060-00010. Drugs R D. 1999. PMID: 10566085 Review.
Ezetimibe.
Bays H. Bays H. Expert Opin Investig Drugs. 2002 Nov;11(11):1587-604. doi: 10.1517/13543784.11.11.1587. Expert Opin Investig Drugs. 2002. PMID: 12437505 Review.
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia.
Davidson MH, Stein EA, Hunninghake DB, Ose L, Dujovne CA, Insull W Jr, Bertolami M, Weiss SR, Kastelein JJ, Scott RS, Campod├│nico S, Escobar ID, Schrott HG, Bays H, Stepanavage ME, Wu M, Tate AC, Melino MR, Kush D, Mercuri M, Mitchel YB; Worldwide Expanded Dose Simvastatin Study Group. Davidson MH, et al. Among authors: bays h. Nutr Metab Cardiovasc Dis. 2000 Oct;10(5):253-62. Nutr Metab Cardiovasc Dis. 2000. PMID: 11213534
294 results